How Glucagon-Like Peptides and Their Receptor Activators Help Manage Heart, Kidney, and Metabolic Conditions

Disclosures R.Z. Alicic is supported by NIH, United States research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project numbers 75D301 to 21-P-12254 and 75D301 to 23-C-18264; and reports other support from Brigham Research Institute, United States, Travere Therapeutics, United States, the Doris Duke Charitable Foundation, United States, Bayer AG, Germany, AstraZeneca, United Kingdom, Novo Nordisk, Denmark, The George Institute for Global Health, Australia, CareDx, United States, and KBP BioSciences, and personal fees from Boehringer Ingelheim, Bayer Pharmaceuticals, and Eli Lilly. J.J. Neumiller is supported by a NIH research grant OT2OD032581 and reports personal fees and other support from American College of Clinical Pharmacy, United States, Bayer AG, Sanofi, United States, Novo Nordisk, Boehringer Ingelheim, United States, Eli Lilly, Proteomics International, and Dexcom, United States.